Compare
Pfizer Inc vs Eli Lilly & Co vs Bristol Myers Squibb Co vs Johnson & Johnson
| Latest fiscal year | Pfizer Inc PFE | Eli Lilly & Co LLY | Bristol Myers Squibb Co BMY | Johnson & Johnson JNJ |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-28 |
| Revenue | $62.58B | $65.18B | $48.19B | $94.19B |
| Revenue growth (YoY) | -1.6% | +44.7% | -0.2% | +6.0% |
| Gross margin | 74.3% (computed) | 83.0% (computed) | n/a | 67.9% |
| Operating margin | n/a | n/a | n/a | n/a |
| Net margin | 12.4% | 31.7% | 14.6% | 28.5% |
| Net income | $7.77B | $20.64B | $7.05B | $26.80B |
| EPS (Diluted) | $1.36 | $22.95 | $3.46 | $11.03 |
| Operating cash flow | $11.70B | $16.81B | $14.16B | $24.53B |
| Free cash flow | $9.07B | n/a | $12.85B | $19.70B |
| Cash & equivalents | $1.14B | $7.27B | $10.21B | $19.71B |
| Total assets | $208.16B | $112.48B | $90.04B | $199.21B |
| Total liabilities | $121.39B | n/a | $71.53B | $117.67B |
| Shareholders' equity | $86.78B | $26.54B | $18.47B | $81.54B |
| Return on year-end equity | 9.0% | 77.8% | 38.2% | 32.9% |
| Shares outstanding | n/a | n/a | n/a | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Pfizer Inc | Eli Lilly & Co | Bristol Myers Squibb Co | Johnson & Johnson |
|---|---|---|---|---|
| Latest | $62.58B Ended 2025-12-31 | $65.18B Ended 2025-12-31 | $48.19B Ended 2025-12-31 | $94.19B Ended 2025-12-28 |
| 1 year earlier | $63.63B Ended 2024-12-31 | $45.04B Ended 2024-12-31 | $48.30B Ended 2024-12-31 | $88.82B Ended 2024-12-29 |
| 2 years earlier | $59.55B Ended 2023-12-31 | $34.12B Ended 2023-12-31 | $45.01B Ended 2023-12-31 | $85.16B Ended 2023-12-31 |
| 3 years earlier | $101.17B Ended 2022-12-31 | $28.54B Ended 2022-12-31 | $46.16B Ended 2022-12-31 | $79.99B Ended 2023-01-01 |
| 4 years earlier | $81.29B Ended 2021-12-31 | $28.32B Ended 2021-12-31 | $46.38B Ended 2021-12-31 | $78.74B Ended 2022-01-02 |